Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: The evidence on the association between pioglitazone use and bladder cancer is contradictory, with many studies subject to allocation bias. The aim of our study was to examine the effect of exposure to pioglitazone on bladder cancer risk internationally across several cohorts. The potential for allocation bias was minimised by focusing on the cumulative effect of pioglitazone as the primary endpoint using a time-dependent approach. METHODS: Prescription, cancer and mortality data from people with type 2 diabetes were obtained from six populations across the world (British Columbia, Finland, Manchester, Rotterdam, Scotland and the UK Clinical Practice Research Datalink). A discrete time failure analysis using Poisson regression was applied separately to data from each centre to model the effect of cumulative drug exposure on bladder cancer incidence, with time-dependent adjustment for ever use of pioglitazone. These were then pooled using fixed and random effects meta-regression. RESULTS: Data were collated on 1.01 million persons over 5.9 million person-years. There were 3,248 cases of incident bladder cancer, with 117 exposed cases and a median follow-up duration of 4.0 to 7.4 years. Overall, there was no evidence for any association between cumulative exposure to pioglitazone and bladder cancer in men (rate ratio [RR] per 100 days of cumulative exposure, 1.01; 95% CI 0.97, 1.06) or women (RR 1.04; 95% CI 0.97, 1.11) after adjustment for age, calendar year, diabetes duration, smoking and any ever use of pioglitazone. No association was observed between rosiglitazone and bladder cancer in men (RR 1.01; 95% CI 0.98, 1.03) or women (RR 1.00; 95% CI 0.94, 1.07). CONCLUSIONS/INTERPRETATION: The cumulative use of pioglitazone or rosiglitazone was not associated with the incidence of bladder cancer in this large, pooled multipopulation analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, more recent studies48,49 showed no significant association for any dose or duration of therapy.49”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [48]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531
Diabetes mellitus and risk of bladder cancer: a meta-analysis
Larsson, S. C., Orsini, N., Brismar, K., & Wolk, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0468-0 · Cited by 304
Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284 · cited 7×
“Furthermore, the study by Neumann et al used never exposed participants as the reference group and did not adjust for smoking.”
BackgroundResultInfluentialAzoulay, L., Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., & Suissa, S. (2012) · BMJ · doi:10.1136/bmj.e3645 · Cited by 270
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E. (2011) · Diabetes Care · doi:10.2337/dc10-2412 · Cited by 239 · cited 1×
“Wei et al [23] UK 2012 66 869 Piccinni et al [19] USA 2011 31 93”
On the Treatment of Grouped Observations in Life Studies
Jr., W. A. T. (1977) · Biometrics · doi:10.2307/2529360 · Cited by 227
Cited by
Items 101–169 of 169
Reduced alcohol use in patients prescribed pioglitazone
Dieperink, E. W., Hauser, P., Dockter, K., Miranda, J. L., Evenson, M., & THURAS, P. D. (2021) · American Journal on Addictions · doi:10.1111/ajad.13214 · Cited by 12
Type 2 Diabetes Mellitus and bladder cancer: A narrative review on associated signaling pathways
Agostini, L. D. C., & da Silva, G. N. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101381 · Cited by 11
Rehabilitation of pioglitazone
Ryder, R. E. J., & DeFronzo, R. A. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.021 · Cited by 11
Han, S., Zhang, X., Li, Z., Cui, G., Xue, B., Yu, Y., Guo, J., Zhang, H., Yang, J., & Teng, L. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114350 · Cited by 10
Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
Fujihara, K., & Sone, H. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00109 · Cited by 10
Antidiabetic effect of SN158 through PPARα/γ dual activation in ob/ob mice
Jung, Y., Cao, Y., Paudel, S., Yoon, G., Cheon, S. H., Bae, G., Jin, L. T., Kim, Y. K., & Kim, S. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.02.014 · Cited by 10
Reversing Advanced Hepatic Fibrosis in NASH: Clearly Possible, but Widely at Hand?
Caldwell, S. H., & Argo, C. K. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3540-0 · Cited by 10
Şekeroğlu, Z. A., Şekeroğlu, V., Yedier, S. K., İlkun, E., & Liou, L. S. (2021) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22424 · Cited by 9
Aoki, C., Suzuki, K., Kuroda, H., Sagara, M., Shimizu, M., Kasai, K., & Aso, Y. (2017) · Institutional Repositories DataBase (IRDB) · doi:10.18999/nagjms.79.1.9 · Cited by 9
Hu, C., Tsai, Y.-C., Wang, S., Huang, C., Tai, H., Chen, C., Pu, Y., Lin, W., & Huang, K. (2015) · BioMed Research International · doi:10.1155/2015/527976 · Cited by 9
PPAR-γ agonist pioglitazone and the risks of malignancy among type2 diabetes mellitus patients
See, L., Wu, C.-Y., Tsai, C., Lee, C., Chen, J., Jenq, C., Chen, C., Chen, Y., Yen, C., & Yang, H. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02378-y · Cited by 8
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8
Pioglitazone: are rumours of its death exaggerated?
Gale, E. (2015) · Diabetic Medicine · doi:10.1111/dme.12708 · Cited by 8
Compendium of polycystic ovarian syndrome and its relevance in glycation and diabetes
Poojari, P., PADGAONKAR, A., Paramanya, A., & Ali, A. H. (2022) · Journal of Experimental and Clinical Medicine · doi:10.52142/omujecm.39.1.49 · Cited by 8
Non-Alcoholic Fatty Liver Disease in Patients with Diabetes Mellitus: A Clinician’s Perspective
Kashanian, S. M., & Fuchs, M. A. (2015) · International Journal of Digestive Diseases · doi:10.4172/2472-1891.100010 · Cited by 8
Reassessment of pioglitazone and bladder cancer based on FAERS database
Chen, H.-Y., Zhao, H., Yang, J., Zhang, Q., Yan, M.-M., & Qiu, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2390000 · Cited by 7
Ryder, R. E. J. (2015) · Diabetic Medicine · doi:10.1111/dme.12736 · Cited by 7
Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter
Ryder, R. E. J. (2015) · Diabetic Medicine · doi:10.1111/dme.12703 · Cited by 7
Nonalcoholic Fatty Liver Disease
Argo, C. K., Henry, Z. H., & Caldwell, S. H. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch32 · Cited by 7
Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2018) · Health Technology Assessment · doi:10.3310/hta21020-c201802 · Cited by 7
Sund, R., & Gissler, M. (2022) · Springer eBooks · doi:10.1007/978-1-4614-6625-3_5-1 · Cited by 6
Self-citationNutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease
Cai, C. X., Carlos, S., Solaimani, P., Trivedi, B. J., Tran, C. T., & Castelino‐Prabhu, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00029-x · Cited by 6
Agrawal, P. K., Jain, A., Gautam, A., Nigam, A. K., Pursnani, N., & Farooqui, M. (2019) · Perspectives in Clinical Research · doi:10.4103/picr.picr_192_18 · Cited by 6
A comprehensive evaluation of anti-diabetic drugs on nuclear receptor PXR platform
Singh, S. K., Yende, A. S., Ponnusamy, K., & Tyagi, R. K. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.06.015 · Cited by 6
Basic Concepts in Insulin Resistance and Diabetes Treatment
Bril, F., & Cusi, K. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-72475-1_3 · Cited by 5
Bowker, S. L., Mu, L., Eurich, D. T., & Johnson, J. A. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.08.227 · Cited by 5
Self-citationDiabetes drugs and the incidence of solid cancers: a survey of the current evidence
Tuccori, M., Convertino, I., Galiulo, M. T., Marino, A., Capogrosso-Sansone, A., & Blandizzi, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361401 · Cited by 5
Ramezannezhad, P., & Khosravifarsani, M. (2023) · Journal of Nephropathology · doi:10.34172/jnp.2023.21443 · Cited by 4
Diagnostic, Therapeutic and Prognostic Implications of Urothelial Carcinoma, A Review
Shahzad, M., Jamil, M. N., Ashraf, H., & Islam, E. U. (2023) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v4i05.720 · Cited by 3
Liang, Z., Chen, L., Liao, Z., Mao, J., Liu, Y., & Li, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01825 · Cited by 3
Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
Schernthaner, G.-H., & Schernthaner, G.-H. (2016) · Herz · doi:10.1007/s00059-016-4427-3 · Cited by 3
Der Zusammenhang zwischen Thiazolidinedionen (Glitazonen) und Blasenkrebs: Ein Rapid Review
Schneidewind, L., Sommerhalder, B., Willi, D., Rönnau, C., Uhlig, A., & Kiss, B. M. (2025) · Die Urologie · doi:10.1007/s00120-025-02557-x · Cited by 3
Pioglitazone—when is a prescription drug safe?
Loke, Y. K., & Mattishent, K. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.237 · Cited by 3
Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?
Cole, N. I., Swift, P. A., Suckling, R., & Andrews, P. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.106 · Cited by 3
Ruzafa, J. C., Ulrichsen, S. P., Bennett, D., & Ehrenstein, V. (2019) · Drugs - Real World Outcomes · doi:10.1007/s40801-019-0160-6 · Cited by 3
A Novel Partial PPARα /γ Dual Agonist SN159 Improves Insulin Sensitivity
Jung, Y., Cao, Y., Paudel, S., Kim, K. H., Yoon, G., Cheon, S. H., Lee, J., Kim, S., & Kim, Y. K. (2016) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.10662 · Cited by 3
Vallabhajosyula, S., Vallabhajosyula, S., Vallabhajosyula, S., Nair, S., Kamath, A., & Rao, K. N. (2016) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2016.06.004 · Cited by 3
Zhuo, L., Xu, J., You, N., Wang, L., Song, Y., Luo, Y., & Shi, J. (2020) · Medicine · doi:10.1097/md.0000000000022867 · Cited by 3
Kodani, E. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-1185 · Cited by 3
Diabetes and Cancer: Evidence for Risk, Methodology and Implications
Badrick, E., & Renehan, A. G. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch54 · Cited by 2
Self-citationPolemics of pioglitazone: an appraisal in 2015
Singh, A. K. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1054809 · Cited by 2
L’internista ospedaliero nella gestione del paziente diabetico complesso
Magnani, G. E. L., Beltramello, G., Brancato, D., Fontanella, A., & Nardi, R. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.q.2018.2 · Cited by 2
Davidson, M. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-22317 · Cited by 2
Pioglitazone Induces Dysplastic Urothelial Changes in Urinary Bladder of Experimental Diabetes
Abdel‐Hamid, A. A. M., & Firgany, A. E. D. (2021) · Journal of Microscopy and Ultrastructure · doi:10.4103/jmau.jmau_34_21 · Cited by 1
Badrick, E., Gallagher, E. J., & Renehan, A. G. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch60 · Cited by 1
Self-citationHu, C., Tsai, Y., Wang, S., Huang, C., Tai, H., Chen, C., Pu, Y., Lin, W., & Huang, K. (2015) · Urological Science · doi:10.1016/j.urols.2015.06.250 · Cited by 1
Gomes, F., Vasconcelos, P., & Pacheco, P. (2017) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/2017.000008.000119 · Cited by 2
Don’t dismiss pioglitazone on basis of uncertain risk
Gallagher, A., & Winocour, P. H. (2016) · BMJ · doi:10.1136/bmj.i3667
Management of Diabetes in the Pre-End-Stage Renal Disease and Chronic Kidney Disease
Molitch, M. E., & Hahr, A. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-08873-0_4
羽田, 裕., 敏正, 山., & 孝, 門. (2015) · 心臓 · doi:10.11281/shinzo.47.951
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis
Sutton, S. K. (2017) · Annals of Internal Medicine · doi:10.7326/l16-0627
Krentz, A. J., & Sinclair, A. J. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch21
Cruz, R. S. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
Obesity: A Complex Disease with Immune Components
Liu, Y., & Clément, K. (2017) · Wiley-VCH eBooks · doi:10.1002/9783527692156.ch46
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_19-1
Biomarkers for non-alcoholic steatohepatitis with special emphasis on lipid metabolism
Männistö, V. (2015) · UEF eRepo (University of Eastern Finland)
Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes
Hahr, A. J., & Molitch, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_23
Study on the Correlation between Bladder Cancer and Metabolic Syndrome
许, 年. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.119587
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_19
Smith, C. K., Sheehan, J. P., & Ulchaker, M. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-04414-9_127
Smith, C. K., Sheehan, J. P., & Ulchaker, M. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_127-1
Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
Peter, P. R., & Inzucchi, S. E. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_37
2015 updated position statement of the management of hyperglycaemia in type 2 diabetes
Scheen, A. J., & Paquot, N. (2015) · ORBi (University of Liège)
Rawat, S., Saraswat, J., Anand, A., Bhati, H., & Patel, R. (2026) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2026.129843
Long-Term Opioid and Gabapentinoid Related Harms in CKD
Grant, C. H., Livingstone, S. J., Wang, H., Barnett, K. N., Mark, P. B., Colvin, L., & Bell, S. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107085
Self-citationAntidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis
MATHEZ, W., Vincentelli, A., Chaoui, I., Bruyère, F., & Bourgi, A. (2026) · Urologia Journal · doi:10.1177/03915603261486088
Metadata
- Authors
- on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., Buchan, I. E., Bowker, S. L., Minhas-Sandhu, J. K., Zafari, Z., Marra, C., Johnson, J. A., Stricker, B. H., Uitterlinden, A. G., Hofman, A., Ruiter, R., de Keyser, C. E., MacDonald, T. M., Wild, S. H., McKeigue, P. M., & Colhoun, H. M.
- Affiliations
- University of Dundee (GB)
- Ninewells Hospital (GB)
- University of Helsinki (FI)
- University of Eastern Finland (FI)
- Universität für Weiterbildung Krems (AT)
- Finnish Cancer Registry (FI)
- Finnish Institute for Health and Welfare (FI)
- University of Manchester (GB)
- University of Alberta (CA)
- University of British Columbia (CA)
- Erasmus MC (NL)
- Groene Hart Ziekenhuis (NL)
- University of Edinburgh (GB)
- Corresponding author
- Bell, Samira
- ORCID
- Venue
- Diabetologia
- Published
- 2014-12-07
- Volume
- 58
- Issue
- 3
- Pages
- 493-504
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2069723602
- Cited by
- 158
- References
- 32
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 9 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 9 · 2018: 14 · 2017: 25 · 2016: 37 · 2015: 33 · 2014: 1
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- WOS
- Funders
- University of Dundee
- European Foundation for the Study of Diabetes
- Medical Research Council (MR/K006665/1, MR/M501633/1, MC_PC_13042, MR/K007017/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, rosiglitazone, bladder cancer, type 2 diabetes, thiazolidinediones, drug-induced cancer risk, cumulative drug exposure, allocation bias, cancer incidence, pooled analysis
- MeSH terms
- Rosiglitazone, Pioglitazone, Aged, Urinary Bladder Neoplasms, British Columbia, Diabetes Mellitus, Type 2, Female, Finland, Humans, Hypoglycemic Agents, Male, Middle Aged, Scotland, Incidence, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.